{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '10. Proficient fluorouracil metabolism as defined:', 'a) Prior treatment with 5-FU or capecitabine without unusal toxicity', 'or', 'b) If tested, normal DPD deficiency test according to the standard of the study site', 'or', 'c) If tested, in patients with DPD deficiency test with a CPIC activity score of 1.0-1.5', 'fluoropyrimidine dosage should be reduced by 50%', '11. For women of childbearing potential (WOCBP): negative pregnancy test within 14 days', 'before randomization and agreement to remain abstinent (refrain from heterosexual', 'intercourse) or use contraceptive methods with a failure rate of < 1% per year during the', 'treatment period and for at least 6 months after the last dose of study treatment.', 'A woman is considered to be of childbearing potential if she is post-menarcheal, has not', 'reached a postmenopausal state (> 12 continuous months of amenorrhea with no identified', 'cause other than menopause), and has not undergone surgical sterilization (removal of', 'ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per', \"year include bilateral tubal ligation, male partner's sterilization, hormonal contraceptives\", 'that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine', 'devices.', 'For men: With female partners of childbearing potential, men must remain abstinent or use', 'a condom plus an additional contraceptive method that together result in a failure rate of', '< 1% per year during the treatment period and for 6 months after the last dose of study', 'treatment. Men must refrain from donating sperm during this same period.', '5.1.2 Exclusion Criteria', 'Participants are excluded from this trial if any of the following criteria apply:', '1.', 'Treatment of metastases greater than 3 cm with radio-frequency/microwave ablation', 'within 24 months prior to study entry if applicable.', '2. Treatment of metastases greater than 5 cm with radiation (stereotactic/ brachytherapy)', 'within 24 months prior to study entry if applicable.', '3. Previous chemotherapy for metastatic or localized disease with > 6 cycles of FOLFOX (or', 'FOLFOXIRI) or > 4 cycles of CAPOX/XELOX.', '4. New York Heart Association Class III or greater heart failure by clinical judgement.', '5. Myocardial infarction within 6 months prior to randomization; percutaneous transluminal', 'coronary angioplasty (PTCA) with or without stenting within 6 months prior to', 'randomization.', '6. Unstable angina pectoris.', '7. Unstable cardiac arrhythmia > grade 2 NCI CTCAE despite anti-arrhythmic therapy.', '8.', 'Ongoing toxicities > grade 2 NCI CTCAE, in particular peripheral neuropathy.', 'Confidential', 'Page 33 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', \"9. Active uncontrolled infection by investigator's perspective.\", '10. Severe chronic non-healing wounds, ulcerous lesions or untreated bone fracture.', '11. Known hypersensitivity to 5-FU, leucovorin, irinotecan or oxaliplatin or to any of the other', 'excipients listed in section 6.1 of the corresponding SmPC.', '12. Bone marrow depression after radio- or chemotherapy.', '13. Severe kidney dysfunction (creatinine clearance < 30 ml/min) or changes in blood count.', '14. Recent or concomitant treatment with brivudine.', '15. Peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to CTCAE', 'version 5.0 (see appendix)).', '16. Inflammatory bowel disease and/or bowel obstruction.', '17. Simultaneous application of Johannis herbs preparations.', '18. Pernicious or other megaloblastic anemia caused by vitamin B12 deficiency.', '19. If tested, DPD deficiency test with a CPIC activity score <1.', '20. Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior', 'to randomization, or abdominal surgery, abdominal interventions or significant abdominal', 'traumatic injury within 21 days prior to randomization or anticipation of need for major', 'surgical procedure during the course of the study or non-recovery from side effects of any', 'such procedure.', '21. Any other disease, metabolic dysfunction, physical examination finding, or clinical', 'laboratory finding that contraindicates the use of an investigational drug, may affect the', 'interpretation of the results, or may render the patient at high risk from treatment', 'complications.', '22. Medical history of malignant disease other than mCRC with the following exceptions:', 'patients who have been disease-free for at least three years before randomization', 'patients with adequately treated and completely resected basal cell or squamous cell', 'skin cancer, in situ cervical, breast or prostate cancer, stage I uterine cancer', 'patients with any treated or untreated malignant disease that is associated with a 5-', 'year survival prognosis of 90% and does not require active therapy', '23. Known alcohol or drug abuse.', '24. Pregnant or breastfeeding females.', '25. Participation in a clinical trial or experimental drug treatment within 28 days prior to', 'potential inclusion in the clinical trial or within a period of 5 half-lives of the substances', 'administered in a clinical trial or during an experimental drug treatment prior to potential', 'inclusion in the clinical trial, depending on which period is longest, or simultaneous', 'participation in another clinical trial while taking part in this clinical trial.', '26. Patients depending on Sponsor, investigator or study site.', '27. Suspected SARS-CoV-2 infection with or without symptoms (evaluation according to local', 'policy in respective center with respect to actual status of pandemic and with reference to', 'Confidential', 'Page 34 of 79']\n\n###\n\n", "completion": "END"}